Vip Peptide

VIP Peptide Overview

Vasoactive Intestinal Peptide (VIP) is a naturally occurring neuropeptide distributed widely through the body, with especially high levels in the brain, gastrointestinal tract, and peripheral nervous system. It functions as a neurotransmitter and neuromodulator, influencing vasodilation, immune regulation, gut motility, and neurological processes. It has been studied for its roles in migraine, inflammatory bowel conditions, and as a possible therapeutic for various gastrointestinal and neurological disorders. As a peptide, it is generally treated as a research chemical, with purity and storage caveats.

Editorial Verdict

VIP is a well-characterized endogenous signaling molecule, but as a supplement it is essentially experimental. There is a wide gap between its established physiology and any proven use as an injected product, and notably, much of the trial evidence demonstrates VIP triggering migraines rather than treating anything. Anyone marketing it as a ready-to-use therapeutic is running ahead of the data.

Evidence Quality

We assign a research grade of B+. The grade rests on 103 peer-reviewed studies: 1 RCT, 6 observational studies, 42 animal studies, 39 in vitro studies, and 14 reviews. Of 103 classified findings, 73 were supportive, 25 mixed, 2 null, and 3 refuting. The human base is thin, with just 1 RCT, so the rating leans heavily on animal and cell-culture work.

What the Research Shows

A review of the gut-brain axis highlights VIP's role in the bidirectional link between the digestive and central nervous systems in migraine. An observational study connected VIP plasma levels to migraine and suggested it may cross the blood-brain barrier and play a part in anxiety and depression. The single randomized trial examined VIP infusion and found it can act as a migraine trigger, reinforcing its role in headache mechanisms rather than as a treatment. In inflammatory bowel disease, circulating VIP levels correlated strongly with clinical activity, with reported sensitivity of 81% and specificity of 55% as a biomarker. Animal work showed L-glutamine supplementation altered VIP-immunoreactive enteric neurons in diabetic rats, and a study in lambs on a high-grain diet found exogenous VIP affected inflammation and intestinal tight-junction integrity. An observational study also examined post-meal VIP secretion in irritable bowel syndrome.

Dosage

There is no established human protocol. In animal studies VIP is given intraperitoneally at doses like 1.3 nmol/kg, while clinical-trial infusions are tightly controlled medical procedures, not consumer dosing. Unlike widely discussed biohacking peptides such as BPC-157, VIP lacks accepted supplementation guidelines, and its effects vary considerably by route, with oral bioavailability being a real limitation.

Who Should Be Cautious

The clearest risk is migraine: VIP infusion can induce migraine-like headaches in susceptible people. Safety data on chronic exogenous use in humans are minimal, its vasoactive nature means cardiovascular effects need monitoring, and the long-term safety profile in healthy people has not been adequately studied.

Availability

VIP is not widely sold as a consumer supplement and is used mainly in research or clinical-trial settings. When available, it would likely carry a "not for human consumption" research-chemical label, and the broader peptide market has well-known problems with fake or impure products, particularly from overseas suppliers. Any therapeutic use would require medical oversight given its potent effects and absence of established safety protocols.

Bottom Line

Real physiology, but as an injectable product it is unproven and under-studied in humans, with the strongest trial evidence pointing to migraines as a risk rather than a benefit.